Plaquenil

D Quensyl (Sanofi Winthrop) I Plaquenil (Maggioni- Rhyumapirine S Q... 

GB Plaquenil (Sanofi Plaquenil (Yamanouchi) USA Plaquenil (Sanofi... 

Hydroxychloroquine, like chloroquine, is also used for treating acute forms of malaria caused by P vivax, P. malariae, P. ovale, and also sensitive forms of P. falciparum. It is also effective and safe like chloroquine, although it does not have obvious advantages. The only advantage is that it is somewhat better tolerated. Its use is somewhat more limited than chloroquine. Synonyms of this drug are plaquenil, quensyl, toremonil, and others. 

Hydroxychloroquine Plaquenil) and chloroquine Ara-len) are 4-aminoquinoline antimalarial drugs that possess modest DMARD activity. They are indicated for the treatment of rheumatoid arthritis and systemic lupus erythematosus their use as antimalarials is detailed in Chapter 53. The onset of action of these drugs is longer than that of other DMARDs, and their side effects are relatively mild. Because of this, these agents show promise as ingredients of combination therapies for rheumatoid arthritis. 

Hydroxychloroquine (Plaquenil), like chloroquine, is a 4-aminoquinoline derivative used for the suppressive and acute treatment of malaria. It also has been used for rheumatoid arthritis and discoid and systemic lupus erythematosus. Hydroxychloroquine has not been proved to be more effective than chloroquine. Adverse reactions associated with its use are similar to those described for chloroquine. The drug should not be used in patients with psoriasis or porphyria, since it may exacerbate these conditions. 

Hydroxychloroquine Plaquenil Oral Up to 6.5 mg/kg of lean body weight per day. Similar to chloroquine. 

Hydroxychloroquine (Plaquenil) is derived chemically from chloroquine and is similar to it in clinical use, mechanism of action, and adverse effects. Hydroxychloroquine does not have any distinct therapeutic advantages over chloroquine, but it may be substituted in certain individuals who do not respond well to chloroquine. 

Salido M, Joven B, D Cruz DP, Khamashta MA, Hughes GR. Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change comment on the letter by Alarcon. Arthritis Rheum 2002 46(12) 3392-6. 

Hydroxychloroquine. In most ways, hydroxychloroquine (Plaquenil) parallels chloroquinc. Structurally, it differs solely in having a hydroxy moiety on one of the /V-cIhyl groups. Like chloroquinc. it remains in Ihc body for over a month, and prophylactic dosing is once weekly. The otha indications, both FDA approved and off-label, arc very. similar. 

Trade names Ercoquin Oxiklorin Plaquenil (Sanofi-Aventis) Plaquinol Quensyl Toremonil Yuma... 

Several 4-aminoquinolines have now been tested and hydroxychloroquine sulphate (Plaquenil XLV, R =Et, R =CH2-CH2-OH), a closely related derivative of chloroquine, is known to possess antirheumatic properties similar to those of chloroquine . Amodiaquine (Camoquin, XLVl, R=NEt2) also possesses activity but seems to be too toxic for routine use . . . However, the closely-related amopyroquin (Propoquin, XLVI, R=pyrrolidino) appears to possess desirable clinical activity without serious toxicity . Drugs of the 4-aminoquinoline type in most frequent use are chloroquine phosphate, 250-500 mg daily, chloroquine sulphate, 200-400 mg daily, and hydroxychloroquine sulphate, 400-600 mg daily . A striking feature of this therapy is that beneficial effects are often not apparent until... 

---